CRSP CRISPR Therapeutics Inc Future Price to Earnings

Official company branding of CRISPR Therapeutics Inc (CRSP)

By creating unique genetic code correction methods to eradicate pathologies, CRISPR Therapeutics AG (CRSP) monetizes the exclusivity of its therapies through high pricing. The launch of Casgevy and partner payments are driving growth, while the company's forward 12-month P/E reflects market expectations, where the value of 0.00 serves as the current metric. This CRISPR/Cas9 leader is ushering in an era of DNA-level treatment for the global market.

Future Price to Earnings Multiple: CRISPR Therapeutics Inc (CRSP) for 07/04/2022 - 11/18/2026

Comprehensive metric breakdowns and analytics for CRISPR Therapeutics AG (CRSP)

- stock value and consensus price forecast:
Fundamental valuation:crisprtx.com
Product sample of CRISPR

The forward P/E reflects the ratio of the current market share price to the expected earnings per share over the next twelve months, allowing for an assessment of the premium paid for future income. The trend of the expected NTM P/E for CRISPR Therapeutics AG (CRSP) demonstrates the valuation's sensitivity to revised earnings forecasts, which is critical for CRISPR Therapeutics AG (CRSP) amid the commercialization of Casgevy and the development of its innovative in vivo editing pipeline.

Competitors of CRISPR Therapeutics AG (CRSP)

Projected Price to Earnings TEM (Tempus AI, Inc)|Qiagen Group (QGEN) - Forward Price to Earnings Multiple|Future Price to Earnings ionispharma.com IONS|Market Cap to Projected Earnings Repligen Corporation (RGEN)|RNA: Projected Price to Earnings|Future Price to Earnings Multiple WGS (GeneDx)|RARE: Forward P/E Multiple|Beam Therapeutics Corp - Future Price to Earnings Multiple|Projected Price to Earnings SRPT|twistbioscience.com (TWST) - Market Cap to Projected Earnings|Forward P/E Multiple TXG|NTLA (Intellia) - Future Price to Earnings Multiple|Future Price to Earnings Stoke STOK|BioLife (BLFS) - Projected Price to Earnings Ratio|wavelifesciences.com - Forward P/E Multiple|Price to Expected Earnings Ratio MAZE|SION: Forward P/E Multiple|PRME - Market Cap to Projected Earnings|Projected Price to Earnings TSHA|QURE - Forward Price to Earnings Multiple|Forward P/E Multiple MGTX|Market Cap to Projected Earnings regenxbio.com|Forward P/E Multiple SLDB (Solid Biosciences Inc)|OCGN: Price to Future Earnings Ratio|PACB - Future Price to Earnings|Benitec (BNTC) - Projected Price to Earnings|DSGN: Forward P/E Multiple|RCKT: Market Cap to Future Earnings Ratio|FDMT (4D Molecular Therapeutics, Inc.) - Forward P/E Multiple|lexeotx.com (LXEO) - Market Cap to Projected Earnings|Forward P/E Multiple KRRO|Projected Price to Earnings Editas Medicine, Inc. EDIT|Future Price to Earnings silence-therapeutics.com SLN|PRQR: Price to Future Earnings Ratio|CDXS - Future Price to Earnings|Market Cap to Projected Earnings Sangamo Therapeutics, Inc. SGMO|NAUT (nautilus.bio) - Projected Price to Earnings|Projected Price to Earnings Ratio Metagenomi, Inc. (MGX)|Projected Price to Earnings DTIL|Price to Future Earnings Ratio GBIO (generationbio.com)|Future Price to Earnings Boundless Bio, Inc (BOLD)|Forward P/E Multiple Exicure Inc. (XCUR)|Imunon, Inc. - Projected Price to Earnings|PHIO: Price to Future Earnings Ratio|MBIO - Future Price to Earnings|Price to Expected Earnings Ratio RNAZ|Bionano Genomics, Inc. (BNGO) - Future Price to Earnings|Applied DNA Sciences, Inc. (APDN) - Forward P/E Multiple|BLUE (bluebirdbio.com) - Forward P/E Multiple|Price to Future Earnings Ratio IPA (ImmunoPrecise Antibodies)|Forward P/E Multiple OMGA|Projected Price to Earnings Singular Genomics Systems OMIC|Forward P/E Multiple RGLS (regulusrx.com)|Syros Pharmaceuticals Inc. (SYRS) - Projected Price to Earnings Ratio|TBIO: Projected Price to Earnings|Future Price to Earnings Multiple TCON (TRACON)|UBX: Forward P/E Multiple